JAZZ — Jazz Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $6.82bn
- $10.92bn
- $3.83bn
- 79
- 75
- 33
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,162 | 2,364 | 3,094 | 3,659 | 3,834 |
Cost of Revenue | |||||
Gross Profit | 2,034 | 2,215 | 2,653 | 3,119 | 3,399 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,629 | 1,991 | 2,924 | 3,725 | 3,256 |
Operating Profit | 532 | 373 | 170 | -65.5 | 579 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 454 | 275 | -113 | -373 | 298 |
Provision for Income Taxes | |||||
Net Income After Taxes | 527 | 242 | -329 | -214 | 418 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 523 | 239 | -330 | -224 | 415 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 523 | 239 | -330 | -224 | 440 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 9.09 | 6.42 | -3.03 | -1.77 | 6.83 |